Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
A Double-Blind, Placebo-Controlled, Randomized, Phase Ib/IIa Clinical Study of ApTOLL for the Treatment of Acute Ischemic Stroke
DRKS00025976Phase 2Completed
- Sponsor
- aptaTargets
- Start
- Aug 2021
- Modality
- Vaccine mRNA → mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 4
01
Overview
A Phase 2 trial of aptoll in ischemic stroke, sponsored by aptaTargets. Started Aug 2021; status: completed.
02
Drugs
aptoll
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on DRKS00025976.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on DRKS00025976.